Desrinit nasal spray 50 mcg/dose 140 doses 18 g
The drug is used intranasally. Inhalation of the suspension contained in the bottle is carried out using a special dispensing nozzle on the bottle. Before using Dezrinit nasal spray for the first time, it is necessary to “calibrate” it. Do not pierce the nasal applicator. To carry out “calibration”, you need to press the dosing nozzle 10 times until splashes appear, which indicates that the drug is ready for use. Tilt your head and inject the medication into each nostril according to the recommended dosage regimen. If the drug has not been used for 14 days or more, press the dispensing nozzle 2 times until splashes appear. Tilt your head and inject the medication into each nostril according to the recommended dosage regimen. Cleaning the dispensing nozzle. It is important to clean the dispensing nozzle regularly to prevent it from malfunctioning. Remove the cap that protects the nozzle from dust, then carefully remove the spray tip. Rinse the spray tip and dust cap thoroughly in warm water and rinse under the tap. Do not try to open the nasal applicator with a needle or other sharp object, as this will damage the applicator, which may result in the patient taking the wrong dose of the drug. Dry the cap and tip in a warm place. After this, attach the spray tip to the bottle and screw the dust cap back onto the bottle. When using the nasal spray for the first time after cleaning, it is necessary to recalibrate by pressing the dispensing nozzle 2 times. Before each use, shake the bottle vigorously. Seasonal and year-round allergic rhinitis. Adults (including older people) and adolescents aged 12 years and older. The recommended preventive and therapeutic dose of the drug is 2 inhalations (50 mcg each) into each nostril 1 time / day (total daily dose - 200 mcg). Upon achieving a therapeutic effect for maintenance therapy, it is possible to reduce the dose by 1 inhalation in each nostril 1 time / day (total daily dose - 100 mcg). If a reduction in the symptoms of the disease cannot be achieved by using the drug at the recommended therapeutic dose, the daily dose can be increased to 4 inhalations into each nostril 1 time per day (total daily dose - 400 mcg). After the symptoms of the disease decrease, a dose reduction is recommended. The onset of action of the drug is usually observed clinically within 12 hours after the first use of the drug. Children aged 2-11 years. The recommended therapeutic dose is 1 inhalation (50 mcg) into each nostril 1 time / day (total daily dose - 100 mcg). To use the drug in young children, adult assistance is required. Adjuvant treatment of acute sinusitis or exacerbation of chronic sinusitis. Adults (including the elderly) and teenagers from 12 years of age. The recommended therapeutic dose is 2 inhalations (50 mcg each) into each nostril 2 times a day (total daily dose - 400 mcg). If a reduction in the symptoms of the disease cannot be achieved by using the drug at the recommended therapeutic dose, the daily dose of the drug can be increased to 4 inhalations into each nostril 2 times a day; total daily dose - 800 mcg. After the symptoms of the disease decrease, a dose reduction is recommended. Treatment of acute rhinosinusitis without signs of severe bacterial infection. The recommended dose for adults and adolescents is 2 inhalations of 50 mcg in each nasal passage 2 times a day (total daily dose 400 mcg). If symptoms worsen during treatment, consultation with a specialist is necessary. Treatment of nasal polyposis. Adults (including older people) over 18 years old. The recommended therapeutic dose is 2 injections (50 mcg each) into each nostril 2 times a day; total daily dose - 400 mcg. After the symptoms of the disease have reduced, it is recommended to reduce the dose to 2 inhalations (50 mcg each) into each nostril 1 time / day (total daily dose - 200 mcg).
Dezrinit
As with any treatment, patients using mometasone nasal spray dosage form for several months or longer should be periodically examined by a doctor for possible changes in the nasal mucosa.
It is necessary to monitor patients receiving intranasal corticosteroids for a long time. Possible development of growth retardation in children. If growth retardation is detected in children, it is necessary to reduce the dose of intranasal corticosteroids to the lowest that allows for effective control of symptoms. In addition, the patient should be referred to a pediatrician for consultation.
If a local fungal infection of the nose or pharynx develops, it may be necessary to discontinue therapy with mometasone in dosage form - dosed nasal spray and carry out special treatment. Irritation of the mucous membrane of the nose and pharynx that persists for a long time can also serve as a basis for discontinuing treatment with mometasone in dosage form - dosed nasal spray.
In placebo-controlled clinical studies in children, when mometasone in dosage form - nasal spray was used in a daily dose of 100 mcg for a year, no growth retardation was observed in children.
With long-term treatment with mometasone in the dosage form - nasal spray, no signs of suppression of the function of the hypothalamic-pituitary-adrenal system were observed.
Patients who switch to treatment with mometasone in dosage form - a dosage nasal spray after long-term therapy with systemic glucocorticosteroids require special attention. Withdrawal of systemic corticosteroids in such patients can lead to adrenal insufficiency, the subsequent recovery of which may take up to several months. If signs of adrenal insufficiency appear, systemic corticosteroids should be resumed and other necessary measures taken.
When using intranasal corticosteroids, systemic side effects may develop, especially with long-term use in high doses. The likelihood of developing these effects is much less than with the use of oral corticosteroids.
Systemic side effects may vary in individual patients and depending on the glucocorticosteroid drug used. Potential systemic effects include Cushing's syndrome, characteristic Cushingoid signs, adrenal suppression, growth retardation in children and adolescents, cataracts, glaucoma, and less commonly a number of psychological or behavioral effects including psychomotor hyperactivity, sleep disturbance, anxiety, depression, or aggression (especially in children).
During the transition from treatment with systemic glucocorticosteroids to treatment with mometasone nasal spray, some patients may experience initial symptoms of systemic glucocorticosteroid withdrawal (for example, joint and/or muscle pain, fatigue and depression), despite a decrease in the severity of symptoms. associated with damage to the nasal mucosa. If these signs appear, you should resume taking systemic glucocorticosteroids and take other necessary measures. Switching from systemic to topical glucocorticosteroids may also reveal pre-existing allergic diseases such as allergic conjunctivitis and eczema that were masked by systemic glucocorticosteroid therapy.
Patients treated with glucocorticosteroids have a potentially reduced immune responsiveness and should be warned of their increased risk of infection if exposed to patients with certain infectious diseases (eg, chickenpox, measles), as well as the need for medical advice if such exposure occurs .
If signs of a severe bacterial infection appear (for example, fever, persistent and sharp pain on one side of the face or toothache, swelling in the orbital or periorbital area), immediate medical consultation is required.
When using mometasone in dosage form - dosed nasal spray for 12 months, there were no signs of atrophy of the nasal mucosa. In addition, mometasone furoate tended to promote normalization of the histological picture when examining biopsy specimens of the nasal mucosa.
The effectiveness and safety of mometasone have not been studied in the treatment of unilateral polyps, polyps associated with cystic fibrosis, and polyps that completely occlude the nasal cavity.
If unilateral polyps of an unusual or irregular shape are detected, especially those that are ulcerated or bleeding, additional medical examination is necessary.
Visual disturbances have been reported with systemic and topical corticosteroid use. If a patient develops symptoms such as blurred vision or other visual disturbances, consider referring the patient to an ophthalmologist to evaluate possible causes, which may include cataracts, glaucoma, or rare diseases such as central serous chorioretinopathy (CSCR).
Desrinit nasal spray. dosage 50mcg/dose 140doses
As with any treatment, patients using mometasone nasal spray dosage form for several months or longer should be periodically examined by a doctor for possible changes in the nasal mucosa. It is necessary to monitor patients receiving intranasal corticosteroids for a long time. Possible development of growth retardation in children. If growth retardation is detected in children, it is necessary to reduce the dose of intranasal corticosteroids to the lowest that allows for effective control of symptoms. In addition, the patient should be referred to a pediatrician for consultation.
If a local fungal infection of the nose or pharynx develops, it may be necessary to discontinue therapy with mometasone in dosage form - dosed nasal spray and carry out special treatment. Irritation of the mucous membrane of the nose and pharynx that persists for a long time can also serve as a basis for discontinuing treatment with mometasone in dosage form - dosed nasal spray.
In placebo-controlled clinical studies in children, when mometasone in dosage form - nasal spray was used in a daily dose of 100 mcg for a year, no growth retardation was observed in children.
With long-term treatment with mometasone in the dosage form - nasal spray, no signs of suppression of the function of the hypothalamic-pituitary-adrenal system were observed.
Patients who switch to treatment with mometasone in dosage form - a dosage nasal spray after long-term therapy with systemic glucocorticosteroids require special attention. Withdrawal of systemic corticosteroids in such patients can lead to adrenal insufficiency, the subsequent recovery of which may take up to several months. If signs of adrenal insufficiency appear, systemic corticosteroids should be resumed and other necessary measures taken.
When using intranasal corticosteroids, systemic side effects may develop, especially with long-term use in high doses. The likelihood of developing these effects is much less than with the use of oral corticosteroids.
Systemic side effects may vary in individual patients and depending on the glucocorticosteroid drug used.
Potential systemic effects include Cushing's syndrome, characteristic Cushingoid signs, adrenal suppression, growth retardation in children and adolescents, cataracts, glaucoma, and less commonly a number of psychological or behavioral effects including psychomotor hyperactivity, sleep disturbance, anxiety, depression, or aggression (especially in children).
During the transition from treatment with systemic glucocorticosteroids to treatment with mometasone nasal spray, some patients may experience initial symptoms of systemic glucocorticosteroid withdrawal (for example, joint and/or muscle pain, fatigue and depression), despite a decrease in the severity of symptoms. associated with damage to the nasal mucosa. If these signs appear, you should resume taking systemic glucocorticosteroids and take other necessary measures. Switching from systemic to topical glucocorticosteroids may also reveal pre-existing allergic diseases such as allergic conjunctivitis and eczema that were masked by systemic glucocorticosteroid therapy.
Patients treated with glucocorticosteroids have a potentially reduced immune responsiveness and should be warned of their increased risk of infection if exposed to patients with certain infectious diseases (eg, chickenpox, measles), as well as the need for medical advice if such exposure occurs .
If signs of a severe bacterial infection appear (for example, fever, persistent and sharp pain on one side of the face or toothache, swelling in the orbital or periorbital area), immediate medical consultation is required.
When using mometasone in dosage form - dosed nasal spray for 12 months, there were no signs of atrophy of the nasal mucosa. In addition, mometasone furoate tended to promote normalization of the histological picture when examining biopsy specimens of the nasal mucosa.
The effectiveness and safety of mometasone have not been studied in the treatment of unilateral polyps, polyps associated with cystic fibrosis, and polyps that completely occlude the nasal cavity.
If unilateral polyps of an unusual or irregular shape are detected, especially those that are ulcerated or bleeding, additional medical examination is necessary.
Visual disturbances have been reported with systemic and topical corticosteroid use. If a patient develops symptoms such as blurred vision or other visual disturbances, consider referring the patient to an ophthalmologist to evaluate possible causes, which may include cataracts, glaucoma, or rare diseases such as central serous chorioretinopathy (CSCR).
Effect on the ability to drive vehicles and machinery There is no data on the effect of the drug Desrinit on the ability to drive vehicles or moving machinery.
